Industry news that matters to you.  Learn more

FDA, EMA Seek Input on Companion Diagnostics, Genomic Biomarkers

Regulators in the U.S. and Europe have each posted requests for public comment on issues affecting the development of medicines by drug companies.

RadMD Presents at BIO International Convention 2011

Dr. Kohkan Shamsi, Principal at RadMD, led one of the key Biomarker sessions at this year’s annual BIO International Convention in Washington DC. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. The Convention also features hundreds of sessions covering biotech trends, policy issues and technological innovations, as well as the world’s largest biotechnology exhibition.

2011 ISB Systems Biology and P4 Medicine Symposium, Day 2

The first Institute for Systems Biology (ISB) symposium was held in 2002. Now in its 10th year, the Systems Biology and P4 Medicine conference provides a setting for some of the world’s most influential researchers who are leading the way in applying systems biology and systems theory to medicine and health care delivery.

UK launches Stratified Medicines Innovation Platform

The UK’s Technology Strategy Board has launched a new programme designed to place the country at the forefront of medicines tailored to smaller and more responsive subsets of patients.

The Stratified Medicines Innovation Platform will bring together researchers, policymakers and the private sector in an initiative drawing on government funding of over £50 million for innovative research and development in areas such as tumour profiling to improve cancer care and biomarker development to enhance drug effectiveness.

Penn Researchers Receive $12 Million NIH Grant to Develop Personalized Approach to Smoking Cessation

A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers’ genetic make-up influences their quitting success.